Cyramza and Folfox for gastric cancer – pro
On 21 April 2014, the US Food and Drug Administration (FDA) approved ramucirumab, as a single agent or with paclitaxel, for treatment of advanced gastric or gastro-esophageal junction adenocarcinoma if the disease has progressed despite fluoropyrimidine- or platinum-containing chemotherapy.Other indications are for lung cancer and colon cancer.
Studies by Yoon and Moore both found that the addition of ramucirumab to front-line mFOLFOX6 did not improve PFS in the ITT population.
H. H. Yoon J. C. Bendell F. S. Braiteh I. Firdaus P. A. Philip A. L. Cohn N. Lewis D. M. Anderson E. Arrowsmith J. D. Schwartz Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial
Annals of Oncology, Volume 27, Issue 12, 1 December 2016, Pages 2196–2203
Moore M, Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
Ann Oncol. 2016 Dec;27(12):2216-2224.